[{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Goldman, Butterwick, Fitzpatrick and Groff","sponsor":"L'Oreal","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Goldman, Butterwick, Fitzpatrick and Groff","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Serum","sponsorNew":"Goldman, Butterwick, Fitzpatrick and Groff \/ L'Oreal","highestDevelopmentStatusID":"9","companyTruncated":"Goldman, Butterwick, Fitzpatrick and Groff \/ L'Oreal"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IAH0968","moa":"HER2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IAH0968","moa":"HER2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Total Definer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Total Definer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Total Definer Research Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Total Definer Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C","highestDevelopmentStatusID":"9","companyTruncated":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Taejoon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CTO0303-A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Taejoon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taejoon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Taejoon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno","sponsor":"Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ARGENTINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Gamma Variant Rbd-Based Arvac-Cg Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno \/ Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory","highestDevelopmentStatusID":"9","companyTruncated":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno \/ Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Human Platelets","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"9","companyTruncated":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"I004","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Curadel Surgical Innovations, Inc.","sponsor":"Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nizaracianine Triflutate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Curadel Surgical Innovations, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curadel Surgical Innovations, Inc. \/ Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai","highestDevelopmentStatusID":"9","companyTruncated":"Curadel Surgical Innovations, Inc. \/ Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai"},{"orgOrder":0,"company":"NTC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NTC015","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"NTC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NTC \/ Undisclosed"},{"orgOrder":0,"company":"Mucosa innovations","sponsor":"Universidad de Granada","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Mucosa innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mucosa innovations \/ Universidad de Granada","highestDevelopmentStatusID":"9","companyTruncated":"Mucosa innovations \/ Universidad de Granada"},{"orgOrder":0,"company":"Vinbiocare Biotechnology Joint Stock Company","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RNA SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Vinbiocare Biotechnology Joint Stock Company","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vinbiocare Biotechnology Joint Stock Company \/ Arcturus Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Vinbiocare Biotechnology Joint Stock Company \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SWIM816","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemirna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Stemirna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Drops","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : CTO0303-A is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 24, 2024

                          Lead Product(s) : CTO0303-A

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Goldman, Butterwick, Fitzpatrick and Groff

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Goldman, Butterwick, Fitzpatrick and Groff

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Details : Vitamin C is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Ascorbic Acid

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : L'Oreal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Gynuity Health Projects

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Gynuity Health Projects

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Lead Product(s) : Levonorgestrel

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase II/ Phase III

                          Sponsor : Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy, Early.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 09, 2024

                          Lead Product(s) : Levonorgestrel

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Jiaxing AnDiCon Biotech

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Jiaxing AnDiCon Biotech

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Details : ADC189 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 02, 2024

                          Lead Product(s) : ADC189

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Curadel Surgical Innovations, Inc.

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Curadel Surgical Innovations, Inc.

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Lead Product(s) : Nizaracianine Triflutate

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase II/ Phase III

                          Sponsor : Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nizaracianine Triflutate is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 26, 2023

                          Lead Product(s) : Nizaracianine Triflutate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : SWIM816 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 20, 2023

                          Lead Product(s) : SWIM816

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

                          Country arrow
                          World Dairy Expo
                          Not Confirmed

                          Lead Product(s) : Gamma Variant Rbd-Based Arvac-Cg Vaccine

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase II/ Phase III

                          Sponsor : Universidad Nacional de San Martín | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Gamma Variant Rbd-Based Arvac-Cg Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          March 02, 2023

                          Lead Product(s) : Gamma Variant Rbd-Based Arvac-Cg Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Universidad Nacional de San Martín | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : IAH0968 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 06, 2023

                          Lead Product(s) : IAH0968

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : I004 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 14, 2022

                          Lead Product(s) : I004

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          World Dairy Expo
                          Not Confirmed
                          World Dairy Expo
                          Not Confirmed

                          Details : PIKA COVID-19 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 19, 2022

                          Lead Product(s) : PIKA COVID-19 Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank